Palatin had mentioned something about the data, from the US trails, could be used in the EU (but I'm sure if that is allowed or not). I think the only way they go the EU route, is if they have a big enough partner to help foot the bill. It sounds like, Gedeon backed out due to the cost associated with the trials in the EU.
One of my assumptions/conspiracies on the Gedeon thing...why they divorced Palatin:
The thing that makes me pause…I was/am under the impression that the cost of trials and the length of trials over there in the EU are, much less costly and shorter in duration then over here in the US. So, let's hope Gedeon didn't find anything negative about the BMT drug in their research.
I'm curious if the breakup is Gedeon just cutting their loss at 12 million, which saved them money, in potential legal fees and lawsuits, etc? Perhaps they know a bit more about the drug. Hopefully, Palatin, is truthful when they say the divorce has nothing to do with BMT or any risk associated with the drug.
LONG $PTN (a tad nervous with Gedeon backing out)
News 
Market Data 
Discover 
